ClinicalTrials.gg
CompletedNCT07523698sliding signUpdated Apr 21, 2026

Vesico-uterin Thickness and Sliding Sign in Term Pregnancies

An interventional study of ultrasound evaluation in Sliding Sign, Vesicouterin Thickness and Term Pregnancy, sponsored by Adana City Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Adana City Training and Research Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

In this study, our aim was to evaluate the relationship of the bladder to the uterus including vesicouterin thickness and sliding sign in term pregnancies with at least one previous cesarean section and compare to controls.

Read the detailed description

The study aimed to evaluate the bladder and uterus ultrasonographically and intraabdominal adhesions prior the cesarean section. Pregnant women aged 18-45 years with singleton, viable third-trimester (37 weeks of gestation or later) pregnancies with the history of at least one previous cesarean section were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective (planned) cesarean delivery and had no obstetric or medical comorbidities. Control group had no history of previous cesarean section. The indications in control group for cesarean section consisted cephalopelvic disproportion and rare other malpresentations.Exclusion criteria included uterine anomalies, intra-abdominal cysts or myomas, multiple pregnancies, a history of additional intra-abdominal surgery, a history of steroid use, collagen disorders, and placental adhesion or invasion anomalies. To ensure homogeneity between groups, patients with comparable body mass index values were preferentially selected.

The patients' obstetric history at the time of admission (gravida, parity, abortion), age, height, weight, gestational age, routine obstetric measurements (fetal position, placental location, amniotic fluid volume, etc.), personal and family history were all recorded. Birth weight and Apgar scores of the newborns were also recorded.

The cesarean scar incision line was visually examined and scored. The scar incision score recorded as inwardly displaced (deplaced), at skin level (flat), or raised (keloid-like).

Stretch marks that form on the abdomen during pregnancy were evaluated and noted according to the proportion they cover when the abdomen was divided into four sections. Stretch mark scores recorded as follows: none for absence of stretch marks, 1/4 for quarter, 1/2 for half and 3/4 for one-third of the abdomen.Intra-abdominal adhesions in patients undergoing cesarean section were classified according to the Nair adhesion scoring system, regardless of prior ultrasound assessment.

Accordingly, the classification recorded as follows: Grade 0: absence of adhesions, Grade 1: presence of a single band of adhesion between the visceral peritoneum and the abdominal surface, Grade 2: presence of two bands of adhesion between the visceral peritoneum and the abdominal surface, Grade 3: presence of three or more bands of adhesion between the visceral peritoneum and the abdominal surface, Grade 4: presence of multiple dense adhesions. The presence of the sliding sign was evaluated as described by Baron et al..The probe was placed just above the transverse skin scar and the patient was asked to take a deep breath or cough in order for the uterus to be observed sliding caudally under the parietal peritoneum and fascia transversalis. Presence of the sliding sign was described "positive" when sliding of the uterus against the abdominal wall was observed. When no movement of the uterus under the fascia, the sliding sign was considered "negative".

The relationship of the bladder to the uterus, whether it was below or above the symphysis pubis were noted. The tissue between the uterus and bladder (vesicouterin thickness) was examined and mesasured.

02

Conditions studied

  • Sliding Sign
  • Vesicouterin Thickness
  • Term Pregnancy
  • Adhesion; Bladder
  • Adhesions Uterus

Browse trials for

Keywords

  • Vesicouterin thickness
  • sliding sign
  • intra-abdominal adhesions
  • repeat Cesarean section
03

In context

Tissue Adhesions

122 studies on the registry are indexed under Tissue Adhesions; 16 are open to participants now.

This study's enrollment of 117 is above the median of 61 across 84 interventional studies indexed under Tissue Adhesions.

Browse Tissue Adhesions studies →

Lead sponsor

Adana City Training and Research Hospital is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-45 years
  • viable singleton third-trimester (37 weeks of gestation or later) pregnancies
  • history of at least one previous cesarean section

Exclusion criteria

Exclusion Criteria:

  • uterine anomalies,
  • intra-abdominal cysts or myomas,
  • multiple pregnancies,
  • history of additional intra-abdominal surgery,
  • history of use, collagen disorders,
  • placental adhesion or invasion anomalies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Active comparator
    intervention (study) group

    repeated cesarean group

    Other: ultrasound evaluation

  • Active comparator
    control group

    primigravid patients

    Other: ultrasound evaluation

Interventions

  • Otherultrasound evaluation

    The probe was placed just above the transverse skin scar and the patient was asked to take a deep breath or cough in order for the uterus to be observed sliding caudally under the parietal peritoneum and fascia transversalis. Presence of the sliding sign was described "positive" when sliding of the uterus against the abdominal wall was observed. When no movement of the uterus under the fascia, the sliding sign was considered "negative".

    Also known as: Sliding sign, vesico-uterin thickness

06

What researchers measure

Primary outcomes

  1. sliding sign

    The probe was placed just above the transverse skin scar and the patient was asked to take a deep breath or cough in order for the uterus to be observed sliding caudally under the parietal peritoneum and fascia transversalis. Presence of the sliding sign was described "positive" when sliding of the uterus against the abdominal wall was observed. When no movement of the uterus under the fascia, the sliding sign was considered "negative".

    Time frame: The study will end when a sufficient number of patients is reached.

  2. Vesicouterin thickness

    The tissue between the uterus and bladder (vesicouterin thickness) was examined and mesasured.

    Time frame: Approximately 6 months. The study will complete when required number of patients reached.

07

Study locations

1 site
  • University of Heath and Science Adana City Hospital
    Adana, Yuregir 01230, Turkey (Türkiye)
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2024, 5 months.

Of 36 interventional studies with no phase under Tissue Adhesions, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartActual
Jan 1, 2024
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 30, 2024
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07523698
Lead sponsor
Adana City Training and Research Hospital
Responsible party
Gulsum Uysal (Ass. Professor Gulsum Uysal, Adana City Training and Research Hospital) — Principal investigator
First posted
Apr 13, 2026
Start date
Jan 1, 2024
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Last update
Apr 21, 2026

Study contacts

Gülsüm Uysal
principal investigator · Department of Obstetrics and Gynecology, University of Health and Science Adana City Training and Research Hospital, Adana, Turkey

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion